Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine/hydroxychloroquine in healthcare setting

IVERSITY OF OXFORD0 个研究点目标入组 40,000 人开始时间: 2020年6月24日最近更新: 2021年1月11日

适应症

试验速览

暂无简介。

•Participant is willing and able to give informed consent for participation in the study and agrees with the study and its conduct
•Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals
•Adults (exact age is dependent on countries)
•Not previously diagnosed with COVID-19
•Not currently symptomatic with an ARI
•Participant A. works in healthcare facility or other well characterised high-risk environment, OR B. is an inpatient or relative of a patient in a participating hospital and likely exposed to COVID-19 infection or another high-risk group
•Possesses an internet-enabled smartphone (Android or iOS)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 37500
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2500

•Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines
•Contraindication to taking chloroquine as prophylaxis e.g. known epileptic, known creatinine clearance < 10 ml/min
•Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines
•Taking a concomitant medication described in section 8.5, which cannot be safely stopped
•Known retinal disease
•Inability to be followed up for the trial period
•Known prolonged QT syndrome (however ECG is not required at baseline)

发起方

IVERSITY OF OXFORD